Status | Study |
Not yet recruiting |
Study Name: Effects of the Prone and the Sitting Positions on the Brain Oxygenation in Posterior Fossa Surgery Condition: Infratentorial Neoplasms Date: 2016-10-10 Interventions: Device: SctO2 The non invasive |
Active, not recruiting |
Study Name: The Effects of Scalp Block on Haemodynamic Response and Postoperative Pain in Posterior Fossa Surgery Condition: Posterior Fossa Tumors Date: 2016-07-26 Interventions: Drug: Bupivacaine In the scalp |
Recruiting |
Study Name: Entinostat in Treating Pediatric Patients With Recurrent or Refractory Solid Tumors Condition: Childhood Brain Stem Neoplasm Childhood Lymphoma Childhood Date: 2016-05-23 Interventions: Drug: Entinostat Given PO |
Recruiting |
Study Name: Nimotuzumab in Combination With Radio-chemotherapy for the Treatment of Brainstem Tumor in Children Condition: Childhood Brain Stem Neoplasm Date: 2016-01-31 Interventions: Drug: Nimotuzumab Nimotuzumab |
Recruiting |
Study Name: Phase I Study of Mebendazole Therapy for Recurrent/Progressive Pediatric Brain Tumors Condition: Medulloblastoma Astrocytoma, Grade III Glioblastoma Date: 2015-12-27 Interventions: Drug: Mebendazole chewable mebendazole tablets that can also be crushed and mixed with food or drink to |
Recruiting |
Study Name: Efficacy of Acetaminophen in Posterior Fossa Surgery Condition: Arnold-Chiari Malformation Posterior Fossa Tumors Date: 2015-08-21 Interventions: Drug: IV acetaminophen IV acet |
Recruiting |
Study Name: Cerebellar Mutism Syndrome Study Condition: Infratentorial Neoplasms Mutism Date: 2014-11-21 |
Recruiting |
Study Name: Fourth Ventricle Infusions of Autologous Ex Vivo Expanded NK Cells in Children With Recurrent Posterior Fossa Tumors Condition: Brain Cancer Date: 2014-10-17 Interventions: Biological: Natural Killer (NK) Cells Starting dose level of NK-cell number per infusion is 10^6/m^2. In |
Recruiting |
Study Name: Impact of Cerebellar Mass Resection on Pain Processing Condition: Cerebellar Neoplasm Date: 2014-10-02 Interventions: Device: Medoc Advanced Medical Systems PATHWAY Model ATS |
Completed |
Study Name: p28 in Treating Younger Patients With Recurrent or Progressive Central Nervous System Tumors Condition: Teratoid Tumor, Atypical Choroid Plexus Neoplasms Anaplast Date: 2013-10-28 Interventions: Drug: azurin-derived cell-penetrating peptide p28 Given IV |